{"title":"Diuretics in Treatment of Heart Failure","authors":"L. B. Seguro, José Leudo Xavier","doi":"10.36660/abchf.20220018","DOIUrl":"https://doi.org/10.36660/abchf.20220018","url":null,"abstract":"","PeriodicalId":231546,"journal":{"name":"ABC Heart Fail Cardiomyop","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122517699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Rethinking the Definition of Heart Failure Based on Ejection Fraction: Reflections with Impact on Therapy","authors":"Marcelo Iorio Garcia","doi":"10.36660/abchf.20220016","DOIUrl":"https://doi.org/10.36660/abchf.20220016","url":null,"abstract":"","PeriodicalId":231546,"journal":{"name":"ABC Heart Fail Cardiomyop","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115632587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sequencing of Pharmacotherapy for Heart Failure with Reduced Ejection Fraction: A Clinical Profile-Based Approach","authors":"L. Beck-da-Silva","doi":"10.36660/abchf.20220007","DOIUrl":"https://doi.org/10.36660/abchf.20220007","url":null,"abstract":"In 1987, a new era of HF treatment began with the publication of the first large randomized clinical trial that tested a drug that could inhibit a hormonal axis involved in causing, maintaining, and increasing risk for this disease. This axis was the renin-angiotensin-aldosterone system (RAAS), and this drug was enalapril.1 At that moment, the addition of a drug to the clinical treatment of patients with HF could reduce relative risk of death by 50%.","PeriodicalId":231546,"journal":{"name":"ABC Heart Fail Cardiomyop","volume":"48 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121743128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Mesquita, Ana Paula Chedid, Lídia Ana Zytynski Moura
{"title":"New Universal Definition of Heart Failure: A New Vision for Treatment","authors":"E. Mesquita, Ana Paula Chedid, Lídia Ana Zytynski Moura","doi":"10.36660/abchf.20220001","DOIUrl":"https://doi.org/10.36660/abchf.20220001","url":null,"abstract":"","PeriodicalId":231546,"journal":{"name":"ABC Heart Fail Cardiomyop","volume":"113 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133618957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pharmacological Treatment Sequencing for Heart Failure with Reduced Ejection Fraction","authors":"F. Marcondes-Braga","doi":"10.36660/abchf.20220006","DOIUrl":"https://doi.org/10.36660/abchf.20220006","url":null,"abstract":"and left bundle branch block morphology. In 2010, ivabradine, a new class of drug for the treatment of HFrEF was described. This drug acts on the sinus node, reducing heart rate (HR), and has been shown to significantly reduce hospitalizations and cardiovascular death in patients in sinus rhythm with LVEF lower or equal to 35% and HR higher or equal to 70 bpm. 9","PeriodicalId":231546,"journal":{"name":"ABC Heart Fail Cardiomyop","volume":"71 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123516834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Treatment of Heart Failure with reduced Ejection Fraction in 2022: The Essential Pillars","authors":"M. Bonatto, A. Coiradas, Lídia Ana Zytynski Moura","doi":"10.36660/abchf.20220003","DOIUrl":"https://doi.org/10.36660/abchf.20220003","url":null,"abstract":"Pharmacological treatment of heart failure with reduced ejection fraction (HFREF) has undergone changes over the years as discoveries have been made related to new systems involved in its pathophysiology and, consequently, of new therapeutic targets. For this treatment, certain drug classes have become essential and should be used in combinations with the objective of reducing the disease’s high rates of morbidity and mortality. They are therefore considered the pillars of treatment for patients with HFREF. These drug classes act on the renin-angiotensin-aldosterone system (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists), on the autonomic nervous system (beta blockers), on the natriuretic peptides system (neprilysin and angiotensin receptor inhibitors), and on the sodium-glucose cotransporter 2 (sodium-glucose cotransporter 2 inhibitors). ¹ This article will present an analytical summary of the pathophysiologic foundations and the scientific evidence that demonstrates the benefit of these medications, specifically in terms of their impact on the results of clinical trials.","PeriodicalId":231546,"journal":{"name":"ABC Heart Fail Cardiomyop","volume":"111 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114015401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thaís Martins de Oliveira, F. Scolari, F. Poswar, F. Oliveira, Ricardo Stein, L. Goldraich
{"title":"Overlapping Etiologies in a Young Patient with Severe Myocarditis: A Case Report","authors":"Thaís Martins de Oliveira, F. Scolari, F. Poswar, F. Oliveira, Ricardo Stein, L. Goldraich","doi":"10.36660/abchf.20220022","DOIUrl":"https://doi.org/10.36660/abchf.20220022","url":null,"abstract":"","PeriodicalId":231546,"journal":{"name":"ABC Heart Fail Cardiomyop","volume":"274 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116555038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Viviane Melo e Silva de Figueiredo, J. V. Santos, Bruna Costa de Albuquerque Bogéa, A. G. Oliveira, José Albuquerque de Figueiredo
{"title":"Pharmacokinetics, Mechanism of Action, and Adverse Effects of the Main Drugs Used to Treat Heart Failure: A Practical Overview for the Clinical Cardiologist","authors":"Viviane Melo e Silva de Figueiredo, J. V. Santos, Bruna Costa de Albuquerque Bogéa, A. G. Oliveira, José Albuquerque de Figueiredo","doi":"10.36660/abchf.20220002","DOIUrl":"https://doi.org/10.36660/abchf.20220002","url":null,"abstract":"","PeriodicalId":231546,"journal":{"name":"ABC Heart Fail Cardiomyop","volume":"73 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130012765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}